Abstract CN8
Background
The SARS-CoV-2 pandemic led many patients to face the difficult decision of weighing the risks and benefits associated with traveling to the hospital for cancer treatment. Driven by this context and motivated by the growing demand for safer and more convenient alternatives, we proposed expanding the administration of low-risk neoplastic treatments to the ambulatory setting. This program has been unprecedented in the Autonomous Community of Cantabria thus far, as there is currently no service that administers chemotherapy outside specialized units in the region's reference hospitals.
Methods
A pilot study was conducted to assess the safety and feasibility of administering low-risk antineoplastic treatments at home at the Marqués de Valdecilla University Hospital, in the city of Santander-Cantabria. The study sample consisted of 139 participants between November 2020 and April 2024. For a patient to be selected to receive treatment at home, they had to meet the following inclusion criteria: firstly, be actively undergoing treatment with low-risk antineoplastic drugs, either subcutaneously or intravenously after the third dose; have a residence in Santander and within a 10-kilometer radius; be at home accompanied by a caregiver between 8:00 and 14:00 on the day of treatment; be able to read and write, or alternatively, have a family member or caregiver available to complete satisfaction questionnaires if necessary. Patients were included in the study only after receiving all the information and providing their consent to participate.
Results
A total of 1,334 cycles were infused in 139 patients from December 2020 to January 2024. The average age of the treated population was 65 years, with 37% being male (n=52) and 63% female (n=87). Breast cancer was the most treated pathology at home (n=59), followed by lung cancer (n=35) and colon cancer (n=12). The most administered drug was trastuzumab (n=47), followed by Pembrolizumab (n=32), Bevacizumab (n=19), and Atezolizumab (n=17). During the pilot program, no adverse infusion reactions were recorded at home.
Conclusions
This project represents a step forward in optimizing oncological care, although further exploration of new ways to improve our patients' treatment experience is still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto de Investigación Valdecilla (IDIVAL).
Funding
IDIVAL, FUPOCAN, AstraZeneca, MSD, Bristol Myers Squibb.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN24 - Experience with the routine use of ePROMs in nurse and pharmacist-led telephone clinics for patients with prostate cancer
Presenter: Kate O'Connor
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN25 - Barriers and facilitators of optimal engagement with teleoncology for older cancer survivors: A rapid review of qualitative literature
Presenter: Carike Barnardo
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN33 - G-8 geriatric screening tool and geriatric nutritional risk index
Presenter: Mehmet Artac
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN34 - Suicide and digestive cancer: A systematic review
Presenter: Diana Lazar
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN35 - Screening recommendations for and outcomes of male patients (pts) with germline BRCA (gBRCA)
Presenter: Heba Mohamed
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN36 - Fasting in cancer patients during chemotherapy: A monocentric study
Presenter: Wala Ben Kridis
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN37 - Use of pictograms (picto) for outpatients treated for cancer and monitored by telehealth: A feasibility and proof of concept study
Presenter: Coralie Boiteau
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN38 - Risk of cardiovascular mortality among cancer survivors in the United States: The role of inflammation
Presenter: Peng Wang
Session: EONS Poster Display session
Resources:
Abstract
CN39 - Exploring the pleasure of eating within children undergoing chemotherapy
Presenter: Malek Khlif
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN40 - Nutritional risk screening (NRS 2002), Prognostic nutritional index (PNI) and Controlling nutritional status (CONUT) in patients with digestive cancer: An observational study
Presenter: Keti Ballfusha
Session: EONS Poster Display session
Resources:
Abstract
Slides